Intro

This chapter explores the groundbreaking use of ketamine and esketamine in treating depression, emphasizing the FDA's approval of esketamine in 2019. The hosts, along with an expert guest, delve into the distinct benefits of these treatments compared to traditional antidepressants, particularly their quick efficacy for treatment-resistant mood disorders.